ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 957,57
0,54%
Dow Jones
38 675,68
1,18%
DAX
18 001,60
0,54%
Brent Oil
82,765
0,00%
Bitcoin
63 038,34
0,24%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Replimune Group Inc (REPL)

  7. Replimune Group Inc (REPL) Actualités

REPL Replimune Group Inc

6,95
0,39 (5,95%)
04 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Replimune Group Inc REPL NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,39 5,95% 6,95 02:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
6,80 6,605 7,08 6,95 6,56
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
07/4/202423:00GLOBEInterim Results from the ARTACUS Clinical Trial of RP1..
04/4/202414:00GLOBEReplimune Announces Inducement Grants Under Nasdaq Listing..
26/3/202412:30GLOBEReplimune Announces Appointment of Sushil Patel to CEO and..
06/3/202414:00GLOBEReplimune to Present at the American Association for Cancer..
05/3/202414:00GLOBEReplimune to Present at Three Upcoming Investor Conferences
14/2/202413:21EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
08/2/202414:09EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/2/202414:05EDGAR2Form 8-K - Current report
08/2/202414:00GLOBEReplimune Reports Fiscal Third Quarter 2024 Financial..
16/1/202410:06PRNUSDISCO Pharmaceuticals launches as the surfaceome company..
16/1/202409:59PRNUSDISCO Pharmaceuticals launches as the surfaceome company..
08/1/202414:00EDGAR2Form 8-K - Current report
28/12/202314:00GLOBEReplimune to Present at the 42nd Annual J.P. Morgan..
26/12/202323:15EDGAR2Form 8-K - Current report
05/12/202313:19EDGAR2Form 8-K - Current report
05/12/202313:00GLOBEReplimune Shares Initial Primary Analysis Results from..
18/11/202302:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/11/202302:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/11/202315:10GLOBEReplimune Presents Updated Data on RP2 in Uveal Melanoma..
07/11/202323:03EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202314:15EDGAR2Form 8-K - Current report
07/11/202314:00GLOBEReplimune Reports Fiscal Second Quarter 2024 Financial..
04/11/202300:30GLOBEReplimune Presents Updated Interim Results from the ARTACUS..
21/9/202302:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/9/202302:03EDGAR2Form 3 - Initial statement of beneficial ownership of..
19/9/202322:01GLOBEReplimune Announces Inducement Grants Under Nasdaq Listing..
19/9/202314:15EDGAR2Form 8-K - Current report
19/9/202314:00GLOBEReplimune Announces Appointment of Emily Hill as Chief..
14/9/202303:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/9/202315:17EDGAR2Form 8-K - Current report
25/8/202302:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/8/202302:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/8/202315:04EDGAR2Form 8-K - Current report
03/8/202314:45EDGAR2Form S-3ASR - Automatic shelf registration statement of..
03/8/202314:11EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/8/202314:09EDGAR2Form 8-K - Current report
03/8/202314:00GLOBEReplimune Reports Fiscal First Quarter 2024 Financial..
01/8/202314:00GLOBEReplimune to Present at Two Upcoming Investor Conferences
31/7/202322:01BWReplimune and Incyte Enter into Clinical Trial Collaboration..
27/7/202302:00EDGAR2Form 3 - Initial statement of beneficial ownership of..
26/7/202323:08EDGAR2Form ARS - Annual Report to Security Holders
26/7/202323:06EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
26/7/202323:02EDGAR2Form DEF 14A - Other definitive proxy statements
20/7/202314:56EDGAR2Form 8-K - Current report
20/7/202314:00GLOBEReplimune Announces Sander Slootweg will Depart from its..
12/7/202303:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/7/202322:27EDGAR2Form 144 - Report of proposed sale of securities
06/6/202316:00GLOBEReplimune Presents Initial RP1 Data from the ARTACUS..
05/6/202314:00GLOBEReplimune Appoints Veleka R. Peeples-Dyer to its Board of..
03/6/202320:15GLOBEReplimune Presents RP1 Data from the IGNYTE anti-PD1 Failed..

Dernières Valeurs Consultées

NASDAQ
REPL
Replimune
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés